当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere.
The Lancet Oncology ( IF 51.1 ) Pub Date : 2020-02-26 , DOI: 10.1016/s1470-2045(20)30082-6 Jean-Luc Raoul 1 , Julien Edeline 2
The Lancet Oncology ( IF 51.1 ) Pub Date : 2020-02-26 , DOI: 10.1016/s1470-2045(20)30082-6 Jean-Luc Raoul 1 , Julien Edeline 2
Affiliation
|
Hepatocellular carcinoma is the fifth most common cancer and second leading cause of cancer-related death globally. More than half of all patients are in China. For nearly 10 years, sorafenib was the only drug to have shown survival benefit in advanced hepatocellular carcinoma. , Regorafenib, lenvatinib, cabozantinib, and ramucirumab have given positive results in phase 3 trials. From 2008 to 2017, however, many phase 3 trials testing new drugs in first or second lines failed, despite promising results observed in the early phases. Reasons for those failures have been discussed previously: poor understanding of drivers of progression, flaws in trial design, underestimation of liver toxicity, marginal antitumour activity, and an absence of trial enrichment with adequate biomarkers of benefit. Many histology-based, molecular-based or immune-based classifications have now been published to assist that enrichment.
更新日期：2020-03-31
京公网安备 11010802027423号